158 related articles for article (PubMed ID: 34780851)
21. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
[TBL] [Abstract][Full Text] [Related]
22. Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.
Ma Y; Du Y; Wang R; Ji X; Wu J; Liu Y; Guo X; Zhang Y
Pathol Res Pract; 2020 Aug; 216(8):153036. PubMed ID: 32703499
[TBL] [Abstract][Full Text] [Related]
23. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of T790M mutation among TKI-therapy resistant Lebanese lung cancer patients based on liquid biopsy analysis: a first report from a major tertiary care center.
Assi H; Tfayli A; Assaf N; Daya SA; Bidikian AH; Kawsarani D; Fermanian P; Zaatari G; Mahfouz R
Mol Biol Rep; 2019 Aug; 46(4):3671-3676. PubMed ID: 31147859
[TBL] [Abstract][Full Text] [Related]
25. A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
Lammers PE; Lovly CM; Horn L
J Natl Compr Canc Netw; 2014 Jan; 12(1):6-11; quiz 11. PubMed ID: 24453288
[TBL] [Abstract][Full Text] [Related]
26. Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.
Wang M; Zhu F; Luo N; Li M; Qi Y; Wang M
Medicine (Baltimore); 2021 Nov; 100(44):e27727. PubMed ID: 34871271
[TBL] [Abstract][Full Text] [Related]
27. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs.
Xu Q; Zhou F; Liu H; Jiang T; Li X; Xu Y; Zhou C
J Thorac Oncol; 2018 Sep; 13(9):1383-1392. PubMed ID: 29852232
[TBL] [Abstract][Full Text] [Related]
28. Identification of epidermal growth factor receptor mutations in pulmonary adenocarcinoma using dual-energy spectral computed tomography.
Li M; Zhang L; Tang W; Jin YJ; Qi LL; Wu N
Eur Radiol; 2019 Jun; 29(6):2989-2997. PubMed ID: 30367185
[TBL] [Abstract][Full Text] [Related]
29. Rapid progressive lung cancers harbouring multiple clonal driver mutations with big bang evolution model.
Kunimasa K; Hirotsu Y; Nakamura H; Tamiya M; Iijima Y; Ishida H; Hamamoto Y; Maniwa T; Kimura T; Nishino K; Goto T; Amemiya K; Mochizuki H; Oyama T; Nakatsuka SI; Kumagai T; Okami J; Higashiyama M; Imamura F; Omata M
Cancer Genet; 2020 Feb; 241():51-56. PubMed ID: 31917104
[TBL] [Abstract][Full Text] [Related]
30. The relationship between EGFR gene mutation status and ERCC1 in lung adenocarcinoma of Chinese patients receiving platinum-based neoadjuvant chemotherapy.
Ke HG; Zhou XY; Shen Y; You QS; Yan Y; Shen ZY
Oncol Res; 2012; 20(5-6):221-9. PubMed ID: 23581229
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Kuang Y; Rogers A; Yeap BY; Wang L; Makrigiorgos M; Vetrand K; Thiede S; Distel RJ; Jänne PA
Clin Cancer Res; 2009 Apr; 15(8):2630-6. PubMed ID: 19351754
[TBL] [Abstract][Full Text] [Related]
32. Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma.
Arfaoui Toumi A; Blel A; Aloui R; Zaibi H; Ksentinini M; Boudaya MS; Znaidi N; Zidi Y; Aouina H; Rammeh Rommani S
Curr Res Transl Med; 2018 Sep; 66(3):65-70. PubMed ID: 29540329
[TBL] [Abstract][Full Text] [Related]
33. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
34. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
35. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
36. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
Tønnesen E; Lade-Keller J; Stougaard M
Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
[TBL] [Abstract][Full Text] [Related]
37. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase.
Dong JK; Lei HM; Liang Q; Tang YB; Zhou Y; Wang Y; Zhang S; Li WB; Tong Y; Zhuang G; Zhang L; Chen HZ; Zhu L; Shen Y
Theranostics; 2018; 8(7):1808-1823. PubMed ID: 29556358
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
39. Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.
Wu K; Guo C; Li R
Medicine (Baltimore); 2019 May; 98(18):e15489. PubMed ID: 31045832
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany.
Schremser K; Rogowski WH; Adler-Reichel S; Tufman AL; Huber RM; Stollenwerk B
Pharmacoeconomics; 2015 Nov; 33(11):1215-28. PubMed ID: 26081300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]